Airsupra (Albuterol Sulfate/Budesonide) Patent Expiration, LOE Window & CMS Spending

Airsupra (Albuterol Sulfate/Budesonide) by AstraZeneca: FDA Orange Book LOE 2030-05-28, 0 AB generics, $40.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN214070 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-05-28
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.6M
2024 Medicare Part D Spend$24.8M
2024 Medicaid Spend$15.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.